Zhitong Finance App News, Sinopharm Hyundai (600420.SH) issued an announcement. Recently, Jiangsu Weiqida Pharmaceutical Co., Ltd., a wholly-owned subsidiary of the company, received the “Notice of Approval of the Application for the Marketing of Chemical Ingredients” for the active drug voronosene fumarate approved and issued by the State Drug Administration. Voronolacin fumarate is a potassium ion competitive acid blocker (P-CAB) that can inhibit gastric acid production and damage to the upper gastrointestinal mucosa. It is mainly used to treat reflux esophagitis and Helicobacter pylori infection.

Disclaimer:Webull uses external vendor Google Translation Service for news translations where we endeavour to ensure these are correct, however, we recommend that you please double-check this information accordingly. Webull is not responsible for translation errors or issues.